Somatostatin and its Analogs.

Area of Science:

• Endocrinology
• Pharmacology
• Oncology

Background:

• Somatostatin (SST) is a peptide hormone that inhibits hormone release and cell proliferation by binding to five somatostatin receptors (SSTRs).
• Long-acting SST analogs like octreotide, lanreotide, and pasireotide are clinically used for conditions such as acromegaly, Cushing's syndrome, and carcinoid syndrome.

Purpose of the Study:

• To review recent advancements in the development and therapeutic applications of somatostatin and its analogs.
• To highlight the evolving role of SST analogs in treating endocrine disorders and cancer.

Main Methods:

• Review of current literature on somatostatin (SST) and its synthetic analogs.
• Analysis of clinical applications and ongoing research into novel SST analog development.
• Examination of the role of SSTRs in cancer and the use of SST analogs in targeted therapeutics.

Main Results:

• SST analogs demonstrate efficacy in treating hormone-related disorders and carcinoid syndrome.
• SSTRs, particularly SSTR2, are frequently overexpressed in various cancers.
• Internalizing SST analogs are being developed as drug-delivery systems for receptor-targeted cancer therapy.

Conclusions:

• Somatostatin analogs are versatile therapeutic agents with established roles in endocrinology and expanding potential in oncology.
• Continued development of novel SST analogs and drug-delivery strategies promises enhanced therapeutic outcomes.
• The aberrant expression of SSTRs in tumors presents a significant opportunity for targeted drug delivery using SST analogs.